title: A rapid response to pembrolizumab in a patient with metastatic melanoma.
abstract: Prognosis for patients with metastatic melanoma stays poor. Recent advances in the field of immuno-oncology increased treatment options for these patients and gave chances for obtaining partial and even complete response, prolonging survival in a subset of patients. Here, we describe a case of a 55-year-old man with multiple melanoma metastases into lungs who showed an extraordinary response to pembrolizumab used as a first-line treatment. The therapy was well tolerated, with no adverse reactions reported.
authors.affiliation: Oncology Department, Huelva Hospital Complex, Ronda Exterior Norte, w/n, 21005 Huelva, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Bayo Calero
authors.affiliation: Oncology Department, Huelva Hospital Complex, Ronda Exterior Norte, w/n, 21005 Huelva, Spain.
authors.forename: Victoria
authors.initials: V
authors.lastname: Aviñó Tarazona
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012074:Remission Induction; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab
keywords: PD-1; immuno-oncology; lung metastases; metastatic melanoma; pembrolizumab